Hao Liu has over 15 years of experience in drug discovery research. He has developed biochemical and cell-based assays to screen for oncology and metabolic disease targets. He is skilled in developing and optimizing high throughput screening assays, cell signaling studies, and molecular biology techniques. Liu has authored several publications and presented at conferences.

1. HAO LIU
24 Woodedge Ave Apt 6, Edison, NJ ● (845) 248-2237 ● hl12345us@yahoo.com
SUMMARY
• Hands on industry drug discovery experience in developing biochemical and cell based assays
for screening assays to support drug discovery.
• Work independently to plan and execute experiments and interpret the results
• Proven ability for working in multicultural team environments
• Excellent written and verbal communication skills
WORK EXPERIENCE
Venenum Biodesign, Hamilton, NJ 12/2015-01/2017
Research Associate, HTS
• Develop, optimize, validate, trouble shoot and execute high through put screening assay for
Oncology target
• Optimize, validate, trouble shoot and execute high through put screening assay for Metabolic
disease target
Biotranx, Monmouth Junction, NJ 11/2014-10/2015
Sr. Research Scientist
• Support in vitro ADME studies CYP 450 induction/inhibition
• Drug transport and drug–drug interaction: ABCB11 induction in primary human hepatocyte/HepG2
using real time qPCR (quantitative PCR)
• PXR/AHR report assay (UGT1A1 qPCR)
• Drug adsorption test: Bi-direction permeability assay in CACO-2 cells, MDCK cells
• Compounds profiling: Med ID, metabolic stability assay Proliferation assay
• Synthesis Protein using vero cell
• Writing SOP
Progenics Pharmaceutical, Tarrytown, NY 09/2010-02/2013
Sr. Research Scientist, Oncology Drug Discovery
• Develop, optimize, validate, trouble shoot and execute Universal, homogeneous, luminescent assay
for kinase for Oncology target
• Develop, optimize, validate, trouble shoot and execute cell based screening assay (In cell Western)
and proliferation assays development
• Studied the intracellular signal transduction cascades and feedback mechanism in multiple tumor
cell lines using combination study to assess mechanism of action and rationalize drug combination
strategy
• Analyze and report the results to the corporate database and project team.
Wyeth Research, Pearl River, NY 04/2001-12/2009
Research Scientist II, Department of Oncology
• Design and develop cell title Glo Assay to screen taxol analogs non-resistant and resistant cell line
• Design and develop cell functional assay: migration assay in HUVEC to identify angiogenesis
antagonist.
• Design and develop DELFIA® assay for screening Survivin, an inhibitor of apoptosis protein.

2. • Develop Homogenous LANCE® (Lanthanide Chelate Excite), TR-FRET Assays (time resolution TR -
fluorescence resonance energy transfer FRET) for NKE2 screening using robotic platform ( biomek)
• Target validation: validate the NEK2 as Oncology target: regulated gene knockdown using lentivirally
based tetracycline dependent ShRNAs.
• Developed expertise in High Content Screening (HCS) for NEK2 project using Cellomics array
scans: target internalization, sub-cellular organelle co-localization
• Gained advanced and extensive experience in implementing Fluorescent Polarization binding assay
for HSP90 project.
• Screening Anti-hFGFR4 monoclonal antibody ( binding assay, neutralization assay, proliferation
assay)
Merck Co. & Inc. Rahway, NJ 04/2000 – 04/2001
Research Scientist, Department of Atherosclerosis & Endocrinology
• Purify and characterize Estrogen Beta receptor monoclonal antibody
• Use Immunohistochemistry and Confocal microscope to identify Erβ isoform tissue distribution in
rat, mouse, and human

3. TECHNICAL SKILLS
Small molecular screening assays
• Biochemical assays:
• Universal, homogeneous, luminescent assay for kinase
• Homogenous LANCE®(Lanthanide Chelate Excite) , TR-FRET Assays (time resolution
TR - fluorescence resonance energy transfer FRET)
• DELFIA® (Dissociation Enhanced. Lanthanide Fluorescent Immunoassay)
• Cellular assay
• Cell based screening assay ( In-cell western ) for evaluating novel therapeutic target
• High Content Screening (HCS) using Cellomics array scans to study lead compounds
cell cycle, morphology
• Cell proliferation assay , drug combination Study
• Reporter gene and gene expression-based assay
• Chemotaxis and apoptosis
Biological screening assay
• ELISA assay: binding assay, Blocking assay (MSD format ) for antibody screening
High through Put Screening
• Proficiency in designing 384 and 1536 well assay and adept with robotics and lab automation
Cell cultures
• Regulated gene knockdown using Inducible lentvirally-transduced tetracycline dependent
ShRNAs.
• Transient /stable transfection, transient/stable cell line generation
Molecular biology skills:
• DNA Subcloning, site-directed mutagenesis , RT-PCR, Real time qPCR
• gene expression
• SDS-PAGE Western blotting, Immunoprecipitation
Cell cycle analysis
• FACS analysis: Guava technologies, Cytosoft 5.3
Software
• Proficiency in Microsoft Office
• Proficiency in Graphpad (Prism)
• Proficiency in Preclinical Database Software: Activity Base and LIMS
EDUCATION
M.S, Molecular and Cellular Biology, Eastern Michigan University, Ypsilanti, MI 1993
Bachelor of Medicine, Pediatrics, Shanghai Second Medical University, Shanghai, China 1988

4. ADDENDUM
PUBLICATIONS
Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent
cell proliferation activity.
Zapf CW1
, Bloom JD, McBean JL, Dushin RG, Nittoli T, Ingalls C, Sutherland AG, Sonye JP, Eid
CN,Golas J, Liu H, Boschelli F, Hu Y, Vogan E, Levin Bioorg Med Chem Lett 2011
Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that
shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.
Zapf CW1
, Bloom JD, McBean JL, Dushin RG, Golas JM, Liu H, Lucas J, Boschelli F, Vogan E,
Levin JI Bioorg Med Chem Lett 2011
Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended
biomarker activity.
Zapf CW1
, Bloom JD, McBean JL, Dushin RG, Nittoli T, Otteng M, Ingalls C, Golas JM, Liu H, Lucas J,
Boschelli F, Hu Y, Vogan E, Levin JI Bioorg Med Chem Lett 2011
Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly
decreases tumor volume in a mouse xenograft model.
Zapf CW1
, Bloom JD, Li Z, Dushin RG, Nittoli T, Otteng M, Nikitenko A, Golas JM, Liu H, Lucas J,
Boschelli F, Vogan E, Olland A, Johnson M, Levin JI Bioorg Med Chem Lett 2011
A cell-based screen for inhibitors of protein folding and degradation,
Frank Boschell,i Jennifer M. Golas, Roseann Petersen, Vincent Lau, Lei Chen, Hao Liu, Qiang Zhao,
Dave Fruhling, Chaneun Nam 2010
Development and comparison of nonradioactive in vitro kinase assays for NIMA-related kinase 2.
Guixian Jin, Ann Aulabaugh, Jennifer Pocas, Hao Liu, Ron Kriz, Deepak Sampath. Anal Biochem
358: 59-69 2006
Preclinical Pharmacological Evaluation of MST-997; An Orally Active Taxane with Superior In
Vitro and In Vivo Efficacy in Paclitaxel and Docetaxel Resistant Tumor Models
Sampath, D., Greenberger, L.M.., Beyer, C., Hari, M., Liu, Hao, Baxter, M.,Yang, S., Rios, C., and
Discafani, C. . Clinical Cancer Research, 12(11) 3459-3469 2006
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath, D., Discafani, C.M., Loganzo, F., Beyer, C., Liu, H., Tan, X., Musto,S., Annable, T., Gallagher,
P., Rios, C., and Greenberger, L.M Molecular Cancer Therapeutics, 2(9): 873-884, 2003
Levels of p21 WAF/CIPI
do not affect radiation-induced cell Death in human breast epithelial cells.
Hyeong-Reh Choi Kim, Gangtoun Li, Harold E. Kim, Sue J. Han, Kazi H. Rahman, Hao Liu, David Waid
and Yong J. Lee Inter. J. of Onco.vol 11. pp1349-1353, 07/1997
High Frequency of Loss of Expression and Allelic Deletion of APC and MCC genes in Human
Prostate Cancer
Xiang Gao, Alex Zacharek, David Grignon, Hao Liu, Wael Sakr, Arthur T. Porter, Yong Q. Chen
&Kenneth V. Honn. Int. J. onco. vol 6. pp 111-117, 07/1995
Bcl-2 suppresses Expression of P21 in Breast Epithelial Cells.
Sunil Upadhyay, Gangyong Li, Hao Liu, Yong Q. Chen, Fazlul H Sarkar, and Hyeong-Reh Choi Kim.
Cancer Research 55,4520-4524, 10/1995
High Frequency of mutator phenotype in human prostatic adenocarcinoma.
Xiang Gao, Ning Wu, David Grignon, Alex Zacharek, Hao Liu, Alicia Salkowski, Gangyong Li, Wael
Sakr, Fazlul Sarkar, Arthur T. Porter, Yong Q. Chen & Kenneth V. Honn Oncogene,Vol.9. pp2999-3003
07/1994

5. ABSTRACTS
Loganzo, F., Annable, T, Tan, X., Musto, S., Morilla, D.B., Hari, M., Liu, H., Sampath, D. and
Greenberger,L.M. Cells made resistant to paclitaxel in the presence of an MDR1-reversible agent
express a -tubulin mutation (Asp26Glu), are less resistant to the novel taxane MAC-321, and are
collaterally sensitive to tubulin depolymerizing agents. Proceedings of the American Association for
Cancer Research, 44 (A5770): 1323, 2003
Sampath, D., Discafani, C.M., Beyer, C., Liu, H., Annable, T., Musto, S., Gallagher, P., Rios, C., Tan,X.,
Loganzo, F., and Greenberger, L.M. MAC-321: A novel taxane with greater efficacy than paclitaxel and
docetaxel in vitro and in vivo. Proceedings of the American Association for Cancer Research, 44
(A5779): 1325, 2003. Oral Presentation
Sampath, D., Discafani, C., Beyer, C., Liu, H., Annable, T., Musto, S., Gallagher, P., Rios, C., Loganzo,
F., Greenberger, L. M. (2004) MST-997: a novel taxane with superior efficacy that overcomes paclitaxel
and docetaxel resistance in vitro and in vivo. European Journal of Cancer, 2 (suppl): 160
H.A. Wilkinson, Hao.Liu, et al Endocrine 2001 Identification and characterization of
a functionally distinct form of human estrogen receptor beta
S.W. Mitra, H.A. Wilkinson, Hao.Liu, et al Endocrine 2001 Characterization of a novel
ERβ antibody and localization of ERβ immunoreactivity in the mouse brain

6. ABSTRACTS
Loganzo, F., Annable, T, Tan, X., Musto, S., Morilla, D.B., Hari, M., Liu, H., Sampath, D. and
Greenberger,L.M. Cells made resistant to paclitaxel in the presence of an MDR1-reversible agent
express a -tubulin mutation (Asp26Glu), are less resistant to the novel taxane MAC-321, and are
collaterally sensitive to tubulin depolymerizing agents. Proceedings of the American Association for
Cancer Research, 44 (A5770): 1323, 2003
Sampath, D., Discafani, C.M., Beyer, C., Liu, H., Annable, T., Musto, S., Gallagher, P., Rios, C., Tan,X.,
Loganzo, F., and Greenberger, L.M. MAC-321: A novel taxane with greater efficacy than paclitaxel and
docetaxel in vitro and in vivo. Proceedings of the American Association for Cancer Research, 44
(A5779): 1325, 2003. Oral Presentation
Sampath, D., Discafani, C., Beyer, C., Liu, H., Annable, T., Musto, S., Gallagher, P., Rios, C., Loganzo,
F., Greenberger, L. M. (2004) MST-997: a novel taxane with superior efficacy that overcomes paclitaxel
and docetaxel resistance in vitro and in vivo. European Journal of Cancer, 2 (suppl): 160
H.A. Wilkinson, Hao.Liu, et al Endocrine 2001 Identification and characterization of
a functionally distinct form of human estrogen receptor beta
S.W. Mitra, H.A. Wilkinson, Hao.Liu, et al Endocrine 2001 Characterization of a novel
ERβ antibody and localization of ERβ immunoreactivity in the mouse brain